{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:36:56Z","timestamp":1793317016034,"version":"4.5.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Shufeng Jiedu (SFJD) capsules can be used as adjunctive treatment for patients with community-acquired pneumonia, but the effectiveness and safety of SFJD are not clear. This review aims to evaluate the effectiveness and safety of SFJD based on randomized controlled trials (RCTs).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A systematic review was conducted by searching PubMed, Embase, Scopus, Web of Science, CENTRAL, CNKI, VIP, CBM, Wanfang and trial registry platforms from their inception to March 2022. Two reviewers screened studies, extracted the data and assessed risk of bias independently. The data were pooled for meta-analysis or presented narratively.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Seventeen RCTs involving 1840 participants were included. All trials compared SFJD plus antibiotics to antibiotics, or combined with symptomatic treatment in both groups. The overall certainty of evidence was assessed as moderate to very low certainty. Compared with routine treatment (antibiotics alone or antibiotics plus symptomatic treatment), SFJD plus routine treatment showed beneficial effects in resolution of fever (MD \u22121.20\u00a0days, 95%CI \u22121.73 to \u22120.67; 10 RCTs; very low certainty), cough (MD \u22121.02\u00a0days, 95%CI \u22121.23 to \u22120.81; 9 RCTs; moderate certainty), phlegm (MD \u22121.46\u00a0days, 95%CI \u22122.84 to \u22120.08; 6 RCTs; very low certainty), pulmonary crepitations (MD \u22121.61\u00a0days, 95%CI \u22122.64 to \u22120.59; 8 RCTs; low certainty), shortness of breath (MD \u22122.80\u00a0days, 95%CI \u22122.88 to \u22122.72; 2 RCTs; low certainty) and chest pain (MD \u22122.85\u00a0days, 95%CI \u22123.01 to \u22122.69; 1 RCT; low certainty). There was no significant difference in pathogen clearance (1 RCT). No serious adverse events were reported, but 2.60% (5\/192) patients reported nausea in the SFJD groups, 1.04% (2\/192) participants in routine group, and no significant difference was identified.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Current evidence suggests that adding SFJD may shorten the duration of symptom relief in community-acquired pneumonia for 1\u20132\u00a0days. The adverse events were minor and controllable, and no serious adverse events were reported. Well-reported trials and potential of reducing antibiotics were expected in the future studies.<\/jats:p>","DOI":"10.3389\/fphar.2022.923395","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T07:04:47Z","timestamp":1656918287000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiao-Wen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-Yu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merlin","family":"Willcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Yuan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Trill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tong","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5365608","DOI":"10.1155\/2019\/5365608","article-title":"The Contribution of Complementary and Alternative Medicine to Reduce Antibiotic Use: A Narrative Review of Health Concepts, Prevention, and Treatment Strategies","volume":"2019","author":"Baars","year":"2019","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5582\/bst.2015.01172","article-title":"Effect of Shufeng Jiedu Capsules as a Broad-Spectrum Antibacterial","volume":"10","author":"Bao","year":"2016","journal-title":"Biosci. Trends"},{"key":"B3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.37201\/req\/114.2020","article-title":"Community-acquired Pneumonia: Similarities and Differences between European and American Guidelines - A Narrative Review -","volume":"34","author":"Barber\u00e1n","year":"2021","journal-title":"Rev. Esp. Quimioter."},{"key":"B4","doi-asserted-by":"publisher","first-page":"538","DOI":"10.7861\/clinmedicine.12-6-538","article-title":"Community-acquired Pneumonia","volume":"12","author":"Brown","year":"2012","journal-title":"Clin. Med. (Lond)"},{"key":"B5","first-page":"651","article-title":"Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia","volume":"29","year":"2006","journal-title":"Chin. J. Tuberc. Respir. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e264621","DOI":"10.1128\/spectrum.02646-21","article-title":"Genetic Diversity and Pathogenic Features in Klebsiella pneumoniae Isolates from Patients with Pyogenic Liver Abscess and Pneumonia","volume":"10","author":"Gan","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1473-3099(17)30396-1","article-title":"Estimates of the Global, Regional, and National Morbidity, Mortality, and Aetiologies of Lower Respiratory Tract Infections in 195 Countries: a Systematic Analysis for the Global Burden of Disease Study 2015","volume":"17","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 354 Diseases and Injuries for 195 Countries and Territories, 1990-2017: a Systematic Analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"B9","first-page":"6437","article-title":"Clinical Observation of Shufeng Jiedu Capsule Combined with Ceftizoxime in the Treatment of Community-Acquired Pneumonia","volume":"35","author":"Guo","year":"2020","journal-title":"China J. Traditional Chin. Med. Pharm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"J. Artic."},{"key":"B11","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3","author":"JPT","year":"20222022"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1164\/rccm.201911-2226LE","article-title":"2019 Community-Acquired Pneumonia Treatment Guidelines: There Is a Need for a Change toward More Parsimonious Antibiotic Use","volume":"201","author":"Huttner","year":"20202019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"109652","DOI":"10.1016\/j.biopha.2019.109652","article-title":"Unique Synergistic Antiviral Effects of Shufeng Jiedu Capsule and Oseltamivir in Influenza A Viral-Induced Acute Exacerbation of Chronic Obstructive Pulmonary Disease","volume":"121","author":"Ji","year":"2020","journal-title":"J. Artic. Pharmacother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3947\/ic.2018.50.2.160","article-title":"Guideline for Antibiotic Use in Adults with Community-Acquired Pneumonia","volume":"50","author":"Lee","year":"2018","journal-title":"Infect. Chemother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.biopha.2017.07.118","article-title":"Anti-inflammatory effects of Shufengjiedu capsule for upper respiratory infection via the ERK pathway","volume":"94","author":"Li","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3969\/j.issn.1007-614x.2020.33.055","article-title":"Observation on the Effect of Shufeng Jiedu Capsule Combined with Antibiotics in the Treatment of Community Acquired Pneumonia","volume":"36","author":"Li","year":"2020","journal-title":"Chin. Community Dr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3969\/j.issn.1004-745X.2020.06.041","article-title":"Effectiveness of Shufeng Jiedu Capsules Combined with Moxifloxacin in the Treatment of Non-severe Community-Acquired Pneumonia","volume":"29","author":"Li","year":"2020","journal-title":"J. Emerg. Traditional Chin. Med."},{"key":"B17","first-page":"2239","article-title":"Evaluation on Clinical Efficacy of Shufeng Jiedu Capsule on Community-Acquired Pneumonia and its Influence on Therapeutic Time of Antibiotic","volume":"30","author":"Li","year":"2015","journal-title":"China J. Traditional Chin. Med. Pharm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.14670\/HH-18-293","article-title":"Shufeng Jiedu Capsules Protect Rats against LPS-Induced Acute Lung Injury via Activating NRF2-Associated Antioxidant Pathway","volume":"36","author":"Liao","year":"2021","journal-title":"Histol. Histopathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and Treatment of Adults with Community-Acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B20","first-page":"1494","article-title":"Diagnosis and Treatment of Corona Virus Disease-19 (8th Trial Deition)","volume":"15","year":"2020","journal-title":"China Med."},{"key":"B21","unstructured":"Announcement of the NMPA on the Conversion of 4 Drugs Including Shufeng Jiedu Capsules to OTC Drugs (2021 No. 90)2021"},{"key":"B22","unstructured":"Pneumonia (Community Acquired): Antimicrobial Prescribing2019"},{"key":"B23","doi-asserted-by":"publisher","first-page":"CD013574","DOI":"10.1002\/14651858.CD013574.pub2","article-title":"Quarantine Alone or in Combination with Other Public Health Measures to Control COVID-19: a Rapid Review","volume":"4","author":"Nussbaumer-Streit","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: an Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B25","first-page":"3224","article-title":"Observation of Shufeng Jiedu Capsules in the Treatment of Wind-Heat Syndrome Community Acquired Pneumonia and its Effects on Cytokines","volume":"35","author":"Pan","year":"2020","journal-title":"China J. Traditional Chin. Med. Pharm."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","article-title":"Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults","volume":"372","author":"Postma","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3969\/j.issn.1004-745X.2019.06.033","article-title":"Clinical Observation of Shufeng Jiedu Capsule Combined with Antibiotics in the Treatment of Community Acquired Pneumonia","volume":"28","author":"Qu","year":"2019","journal-title":"J. Emerg. Traditional Chin. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults Hospitalized with Pneumonia in the United States: Incidence, Epidemiology, and Mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ijsu.2011.09.004","article-title":"CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials","volume":"9","author":"Schulz","year":"2011","journal-title":"Int. J. Surg."},{"key":"B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41479-020-00074-3","article-title":"Etiology of Community-Acquired Pneumonia in Adults: a Systematic Review","volume":"12","author":"Shoar","year":"2020","journal-title":"Pneumonia (Nathan)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"E28286","DOI":"10.1097\/MD.0000000000028286","article-title":"Analysis of the Active Components and Mechanism of Shufeng Jiedu Capsule against COVID-19 Based on Network Pharmacology and Molecular Docking","volume":"101","author":"Simayi","year":"2022","journal-title":"Medicine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a Revised Tool for Assessing Risk of Bias in Randomised Trials. [Comment; Journal Article]","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B33","doi-asserted-by":"publisher","first-page":"8362","DOI":"10.1016\/j.vaccine.2020.11.004","article-title":"Incidence of Community-Acquired Pneumonia in Urban China: A National Population-Based Study","volume":"38","author":"Sun","year":"2020","journal-title":"Vaccine"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1021\/acs.jproteome.7b00409","article-title":"Therapeutic Mechanistic Studies of ShuFengJieDu Capsule in an Acute Lung Injury Animal Model Using Quantitative Proteomics Technology","volume":"16","author":"Tao","year":"2017","journal-title":"J Proteome Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3969\/j.issn.1671-945X.2021.01.066","article-title":"Evaluation of the Efficacy and Safety of Shufeng Jiedu Capsule Combined with Antibiotics in the Treatment of CAP","volume":"19","author":"Tang","year":"2021","journal-title":"J. China Prescr. Drug"},{"key":"B35","doi-asserted-by":"publisher","first-page":"104243","DOI":"10.1016\/j.jff.2020.104243","article-title":"Systematic Analyses on the Potential Immune and Anti-inflammatory Mechanisms of Shufeng Jiedu Capsule against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Caused Pneumonia","volume":"75","author":"Tao","year":"2020","journal-title":"J. Funct. Foods"},{"key":"B36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.7619\/jcmp.202019012","article-title":"Efficacy of Shufeng Jiedu Capsule Combined with Moxifloxacin in the Treatment of Community-Acquired Pneumonia","volume":"24","author":"Wang","year":"2020","journal-title":"J. Clin. Med. Pract."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3969\/j.issn.1673-7202.2016.08.032","article-title":"Efficacy Analysis of Shufeng Jiedu Capsule in Treating Community-Acquired Pneumonia","volume":"11","author":"Wang","year":"2016","journal-title":"World Chin. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3969\/j.issn.1004-745X.2016.09.060","article-title":"Clinical Effectiveness of Shufeng Jiedu Capsules Combined with Antibiotics in the Treatment of Community-Acquired Pneumonia","volume":"25","author":"Wei","year":"2016","journal-title":"J. Emerg. Traditional Chin. Med."},{"key":"B39","unstructured":"Pneumonia2021"},{"key":"B40","unstructured":"Revised WHO Classification and Treatment of Childhood Pneumonia at Health Facilities - EVIDENCE SUMMARIES2014"},{"key":"B41","first-page":"413","article-title":"Clinical Study on Shufeng Jiedu Capsule Combined with Cefoperazone Sodium and Sulbactam Sodium in the Treatment of Community Acquired Pneumonia","volume":"26","author":"Wu","year":"2019","journal-title":"Pharm. Biotechnol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"153390","DOI":"10.1016\/j.phymed.2020.153390","article-title":"Shufeng Jiedu, a Promising Herbal Therapy for Moderate COVID-19:Antiviral and Anti-inflammatory Properties, Pathways of Bioactive Compounds, and a Clinical Real-World Pragmatic Study","volume":"85","author":"Xia","year":"2021","journal-title":"Phytomedicine Int. J. phytotherapy Phytopharm."},{"key":"B43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12906-020-02924-5","article-title":"Shufeng Jiedu Capsules for Treating Acute Exacerbations of Chronic Obstructive Pulmonary Disease: a Systematic Review and Meta-Analysis","volume":"20","author":"Xia","year":"2020","journal-title":"BMC Complement. Med. Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.16305\/j.1007-1334.2016.07.004","article-title":"Guidelines for Integrated Traditional Chinese and Western Medicine in the Treatment of Community-Acquired Pneumonia( Basic Edition of Shanghai 2015)","volume":"50","author":"Xiong","year":"2016","journal-title":"Shanghai J. Traditional Chin. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.19540\/j.cnki.cjcmm.20210712.501","article-title":"An Overview of Systematic Review on Shufeng Jiedu Capsules","volume":"47","author":"Xu","year":"2022","journal-title":"China J. Chin. Materia Medica"},{"key":"B46","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jinf.2020.02.016","article-title":"Clinical Characteristics and Imaging Manifestations of the 2019 Novel Coronavirus Disease (COVID-19):A Multi-Center Study in Wenzhou City, Zhejiang, China","volume":"80","author":"Yang","year":"2020","journal-title":"J. Infect."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.668407","article-title":"Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.15932\/j.0253-9713.2016.11.040","article-title":"Shufeng Jiedu Capsules for Non-severe Community-Acquired Pneumonia: A Clinical Randomized Trial","volume":"38","author":"Yao","year":"2016","journal-title":"Beijing Med. J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"350","DOI":"10.13288\/j.11-2166\/r.2019.04.019","article-title":"Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia (2018 Revision)","volume":"60","author":"Yu","year":"2019","journal-title":"J. Traditional Chin. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1159\/000494184","article-title":"Shufeng Jiedu Capsules Alleviate Lipopolysaccharide-Induced Acute Lung Inflammatory Injury via Activation of GPR18 by Verbenalin","volume":"50","author":"Yuan","year":"2018","journal-title":"Cell. Physiology Biochem."},{"key":"B51","first-page":"1471","article-title":"Effect Evaluation for Shufeng Jiedu Capsule in the Treatment of the EIderly Patients with Community-Acquired Pneumonia","volume":"16","author":"Zhang","year":"2014","journal-title":"Chin. J. Med. Guide"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.15932\/j.0253-9713.2016.10.046","article-title":"Clinical Observation of Shufeng Jiedu Capsule Combined with Levofloxacin in the Treatment of Community-Acquired Pneumonia without Increased Peripheral Blood Leukocytes","volume":"38","author":"Zhang","year":"2016","journal-title":"Beijing Med. J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"100726","DOI":"10.1016\/j.imr.2021.100726","article-title":"Chinese Patent Herbal Medicine (Shufeng Jiedu Capsule) for Acute Upper Respiratory Tract Infections: A Systematic Review and Meta-Analysis. [Journal Article; Review]","volume":"10","author":"Zhang","year":"2021","journal-title":"Integr. Med. Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3969\/j.issn.1004-745X.2019.08.040","article-title":"Clinical Observation of Shufeng Jiedu Capsule Combined with Moxifloxacin in the Treatment of Community-Acquired Pneumonia","volume":"28","author":"Zhou","year":"2019","journal-title":"J. Emerg. Traditional Chin. Med."},{"key":"B55","first-page":"134","article-title":"Effect Observation of Shufeng Jiedu Capsules in the Treatment of Community-Acquired","volume":"23","author":"Zhu","year":"2016","journal-title":"China Mod. Med."},{"key":"B56","first-page":"163","article-title":"Effect Observation of Shufeng Jiedu Capsule Combined with Amoxicillin and Clavulanate Potassium in the Treatment of Mild Pediatric Pneumonia","volume":"22","author":"Zou","year":"2015","journal-title":"China Mod. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.923395\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T07:05:04Z","timestamp":1656918304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.923395\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":58,"alternative-id":["10.3389\/fphar.2022.923395"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.923395","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"article-number":"923395"}}